Provided by Tiger Trade Technology Pte. Ltd.

Biocryst Pharmaceuticals

9.70
-0.1200-1.22%
Post-market: 9.62-0.0800-0.82%19:57 EDT
Volume:2.76M
Turnover:26.56M
Market Cap:2.48B
PE:-6.44
High:9.72
Open:9.72
Low:9.46
Close:9.82
52wk High:11.22
52wk Low:6.00
Shares:255.54M
Float Shares:222.00M
Volume Ratio:1.21
T/O Rate:1.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5054
EPS(LYR):1.21
ROE:587.33%
ROA:52.86%
PB:-5.46
PE(LYR):8.02

Loading ...

BioCryst Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
May 07

BUZZ-U.S. STOCKS ON THE MOVE-Walt Disney, CVS, Uber

Reuters
·
May 06

Stock Track | BioCryst Pharmaceuticals Plunges 6.98% Pre-Market on Surprise Quarterly Loss

Stock Track
·
May 06

Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q1 Net Loss $2.98 a Share, vs. FactSet Est of $0.04 EPS

MT Newswires Live
·
May 06

BioCryst Pharma Q1 Adj. EPS $0.14 Beats $0.05 Estimate, Sales $156.413M Beat $151.123M Estimate

Benzinga Earnings
·
May 06

BioCryst Q1 operating loss widens to $701.6 million; ORLADEYO revenue rises 11% to $148.3 million

Reuters
·
May 06

BRIEF-BioCryst Pharmaceuticals Q1 EPS USD -2.98

Reuters
·
May 06

BioCryst Pharmaceuticals Inc - Maintains FY2026 Non-Gaap Operating Expense Guidance $450 Mln-$470 Mln

THOMSON REUTERS
·
May 06

BioCryst Pharmaceuticals Q1 Operating Expenses USD 858.011 Million

THOMSON REUTERS
·
May 06

BioCryst Pharmaceuticals Q1 Product Sales USD 3.016 Million

THOMSON REUTERS
·
May 06

Corrected-BioCryst Pharmaceuticals Q1 Product Sales USD 148.3 Million (Corrects Amount)

THOMSON REUTERS
·
May 06

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

THOMSON REUTERS
·
May 06

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 06

Top News Today: Stocks Rise, Oil Falls, as War Restart Fears Subside

Dow Jones
·
May 06

BioCryst grants 61,750 RSUs to six new hires under inducement plan

Reuters
·
May 05

BioCryst licenses navenibart Europe rights to Neopharmed Gentili affiliate for $70 million upfront

Reuters
·
May 04

BioCryst Pharmaceuticals Inc - to Receive Tiered Royalties of 18%-30% on Net Sales

THOMSON REUTERS
·
May 04

BioCryst Pharmaceuticals Inc - to Receive $70 Mln Upfront and up to $275 Mln in Milestone Payments

THOMSON REUTERS
·
May 04

BioCryst Pharmaceuticals Inc - Navenibart Phase 3 Program on Track for US Regulatory Filing by End of 2027

THOMSON REUTERS
·
May 04

BioCryst Announces European Licensing Agreement With Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

THOMSON REUTERS
·
May 04